Exploring the Infinite Potential of the Peptide Industry: 2024 Peptide Industry Innovation and Development Conference to Launch Soon!

As a highly prominent branch of the biopharmaceutical sector, the peptide industry has demonstrated vigorous growth in recent years. Driven by rapid advancements in biotechnology and heightened public health awareness, peptide drugs have gained significant favor as a promising therapeutic modality characterized by high efficacy, low toxicity, and high selectivity.

First, the peptide industry has demonstrated significant potential in the field of drug development. Due to the superior inherent structural properties of peptide molecules, peptide-based therapeutics offer unique advantages in the treatment of cancer, immune modulation, and neurological disorders. In recent years, numerous peptide drugs have advanced into clinical trials, exhibiting favorable efficacy and safety profiles, thereby bringing new hope to clinical treatment.

Secondly, the application of the peptide industry in the field of biotechnology is becoming increasingly extensive. Peptides not only play a crucial role in drug development but are also widely used in areas such as biomaterials, diagnostic reagents, and biosensors. For instance, the application of peptides in biomaterials can enhance their biocompatibility and bioactivity, thereby driving innovation and development in medical materials.

Moreover, the peptide industry is demonstrating robust growth in terms of market demand. With population aging and the rising prevalence of chronic diseases, there is an increasing demand for drugs that are highly efficacious, low in toxicity, and highly selective, thereby creating substantial market space and development opportunities for the peptide sector. Coupled with continuous advancements in biotechnology and synthetic biology, the R&D and production costs of peptide drugs are gradually decreasing, further enhancing their competitiveness.

To promote innovation and development in the peptide industry, “2024 Peptide Industry Innovation and Development Conference”(hereinafter referred to as the “Conference”) will be held in Nanjing from April 16 to 18, 2024. It aims to establish a platform for matchmaking and collaboration, bringing together industry experts, entrepreneurs, research scholars, and representatives of investment institutions to discuss the latest developments, future trends, and R&D innovation directions in the peptide industry, thereby promoting the rapid development of China’s peptide industry.

In recent years, the peptide industry has developed rapidly and is receiving increasing attention. Meanwhile, as an emerging sector, it faces numerous challenges in technological innovation, industry development, and industrial translation.

The purpose of this conference is to bring together diverse stakeholders from the industry, including researchers, entrepreneurs, and investment institutions, to jointly explore the direction and strategies for industry development, promote technological and business model innovation in the peptide industry, accelerate the translation and application of new technologies, and drive the peptide industry toward a higher level of advancement.

The conference showcased three major highlights:

First, extensive agenda setting. The conference will cover multiple key topics, including R&D progress in peptide drugs, market development trends, production technologies, and application areas.

Second, the conference will cover the entire upstream and downstream value chain of the peptide drug industry. It will address all key stages, including raw materials, drug design and R&D, manufacturing processes, and industrialization. Furthermore, it will explore the innovative potential of peptides in cross-disciplinary fields such as medical aesthetics and artificial intelligence, providing new insights and directions for the future development of the peptide industry.

Third, Showcase of Frontier Technologies and Innovative Achievements. The conference will share and analyze frontier dynamics in the peptide industry, including research achievements, technological innovations, and future directions. Examples include AI-driven peptide drug development, the development and industrialization of marine bioactive peptides, and peptide synthesis using unprotected amino acids.

The research, development, and application of peptide drugs are not confined to the pharmaceutical sector but also intersect and integrate with multiple disciplines, including bioengineering, materials science, and information technology. Therefore, promoting innovation and development in the peptide industry requires coordinated efforts across industry, academia, research, and clinical application, as well as cross-disciplinary collaboration among fields such as biotechnology, drug discovery, and artificial intelligence.

In light of this, the conference has invited experts, scholars, and representative enterprises from various segments of the entire peptide industry chain to participate. During the event, attending experts and companies will share their latest achievements and practical applications in the field of peptides, pool resources from all sectors of the industry, promote collaboration among industry, academia, research, and end-users, jointly explore development directions and strategies for the peptide industry, and drive China’s peptide industry toward higher levels of advancement.

Below is the registration channel for this exhibition. Exhibition area admission tickets are free for a limited time, while Conference Business/VIP tickets are available at a limited-time discount. The number of discounted All-Access Conference passes is limited and will be allocated on a first-come, first-served basis. We look forward to your participation!

Exhibition Area Conference TicketLimited-Time Free Access

Conference Business Ticket/VIP TicketLimited-Time Offer

Limited quantity, available on a first-come, first-served basis.

April 17 Conference Agenda

09:00-09:10

Opening Remarks

09:10-09:40

Research and Development of PACAP-Derived Peptide-Receptor Agonists

Hong An, Vice President of Jinan University, Researcher/Distinguished Professor and Director of the Institute of Biotechnology

09:40-10:10

Research and Development of Long-Acting Peptide Drugs and the Trend Toward Green Industrialization

Lu Rongjian, Vice President, Aivita Biomedical

10:10-10:40

Discovery and Clinical Translation of Innovative Dual-Target Agonists Targeting GLP-1R/GIPR

Fang Yongliang, Daoer Bio, Chief Operating Officer

10:40-11:00

Tea Break

11:00-11:30

R&D of Neuropeptide Drugs for the Nervous System

Chen Jinhui, Founder of Suzhou Glancore Pharmaceutical Technology Co., Ltd., Senior Associate Professor at Xi’an Jiaotong-Liverpool University

11:30-12:00

Global Trends in the Peptide Drug Market

Chen Zhenrong, Sullivan, Senior Director of Peptide Projects

12:00-13:30

Lunch Time

13:30-14:00

Development of Novel PDC Drugs Such as Peptide-Glycosaminoglycans

Zhang Puwen, General Manager, Zhejiang Handing Pharmaceutical Co., Ltd.

14:00-14:30

Novel Strategies for Constructing Fluorescent Cyclic Peptides and Recent Advances in the Design of Peptide-Drug Conjugates

Zhu Qing, Professor, College of Biotechnology and Bioengineering, Zhejiang University of Technology

14:30-15:00

TBD

Zhang Yingqi, Professor, Department of Biopharmaceuticals, School of Pharmacy, Air Force Medical University

15:00-15:20

Tea Break

15:20-15:50

Research and Development of Peptide-Drug Conjugates

Xu Hanmei, Chairman, Nanjing Anji Biotechnology Co., Ltd.

15:50-16:20

Natural Peptides and Drug Development

Rong Mingqiang, Chairman of Chengdu Peide Biopharmaceutical Co., Ltd. and Professor at Hunan Normal University

April 18 Conference Agenda

09:00-09:30

Green Continuous Peptide Synthesis: From Laboratory to Industrial Application

Su Xianbin, Professor, Nanjing Tech University

09:30-10:00

Unprotected Amino Acid Synthesis of Polypeptides

Zhao Junfeng, Guangzhou Medical University, Professor

10:00-10:30

Inviting

10:30-10:50

Tea Break

10:50-11:20

Applications of Artificial Intelligence in Peptide Drug Development

Zhang Xiao, Chengyuan Technology, Co-Founder and CEO

11:20-11:50

R&D of GLP-1/GLP-2 Drugs Based on the TE-PEP Technology Platform

Wen Jun, Executive Deputy General Manager, Chongqing Paijin Biotechnology

11:50-13:30

Lunch Time

11:30-14:00

Development and Industrialization of Marine Bioactive Peptides

Bao Weiyang, Chairman, Dalian Shenlan Peptide Technology R&D Co., Ltd.

14:00-14:30

Synthetic Biology Development and Application of Bioactive Cosmetic Peptides

Fan Kai, Chairman and General Manager of Chongqing Fujin Biopharmaceutical Co., Ltd.

14:30-15:00

Inviting

15:00-15:20

Tea Break

15:20-15:50

Bactericidal Effect of Novel Antimicrobial Peptides Against Drug-Resistant Aeromonas hydrophila

Sun Leisheng, Assistant Professor, School of Medicine, Hunan Normal University

15:50-16:20

Research on Broad-Spectrum Anti-Coronavirus Peptide Inhibitors

Xia Shuai, Researcher at the School of Basic Medical Sciences, Fudan University